#Canada #Brenig Therapeutics #Whistler #BT-409 #NLRP3 Inhibitor

Brenig Therapeutics Presents Innovative AI-Driven NLRP3 Inhibitor Research

Brenig Therapeutics Inc., a notable player in biotechnology, is at the forefront of trying to combat neurodegenerative diseases with innovative treatments. The company is preparing for a significant presentation at the Keystone Symposia on Neuroinflammation in Health and Disease, where it will unveil new data on its brain-penetrant NLRP3 inhibitor, BT-409, which has shown promise in treating Parkinson's disease and related neuroinflammatory disorders.

At this major conference, Dr. Alexei Pushechnikov will present a poster titled "AI-Enabled Design of a Brain-Penetrant NLRP3 Inhibitor for Neuroinflammation in Parkinson's Disease." This revealing presentation will showcase how Brenig has utilized its cutting-edge Hybrid AI Platform, successfully developed in partnership with Expert Systems, Inc., to expedite the design of effective treatments that can penetrate the blood-brain barrier.

The poster presentation takes place on Tuesday, June 23, 2026, at the Fairmont Chateau Whistler in Whistler, British Columbia, Canada, during the first poster session at 7:30 PM PT. Targeting an audience keen on learning about the intricate connections between neuroinflammation and chronic conditions like Parkinson's, the poster aims to expose new pathways for therapeutic development.

Brenig's AI-driven approach incorporates advanced structural biology and modern machine learning, enabling the team to tackle previous barriers that have hindered CNS drug discovery. Traditional methods often necessitated a compromise between potency, selectivity, and brain exposure, making it substantially challenging to develop neutron-targeted drugs that meet these rigorous requirements. Dr. Pushechnikov will illustrate how the use of molecular dynamics simulations, combined with AI optimization, allows for concurrent refinement of drug properties, thereby enhancing the effectiveness of the design-make-test cycles.

Dr. Pushechnikov shares, "Neuroinflammation plays a critical role in the progress of neurodegenerative diseases, and targeting the NLRP3 inflammasome has proven to be both attractive yet challenging. Our collaborative efforts with Expert Systems facilitate a discovery engine that can explore chemical space with an unprecedented level of precision, improving our strategy to design selective and effective NLRP3 inhibitors.”

The presentation will underscore not just BT-409 but also touch on how this hybrid method has contributed to Brenig's other clinical-stage program, BT-267, which focuses on a selective LRRK2 inhibitor for addressing Parkinson's disease. Brenig acquired BT-409 from Mwyngil Therapeutics, further pushing forward with clinical advancements of this promising candidate. The two programs exemplify how Brenig's platform can generate compounds with exceptional pharmacologic characteristics, underpinning the company’s goal to produce best-in-class therapies against debilitating diseases.

CEO Megan McGill, MD, PhD, adds, “Our progress exemplifies the potential of our AI-optimized platform. By effectively coupling selectivity with brain penetration, we are succeeding where many have struggled. BT-409 represents our commitment to developing therapies that meaningfully address the neuroinflammatory parameters driving diseases like Parkinson's.”

Brenig Therapeutics stands tall as a pioneer in leveraging artificial intelligence to revolutionize the approach to neurodegenerative and neuroinflammatory disorders. As the team gears up for the upcoming symposium, the anticipation builds around their progress and future endeavors, setting the stage for what could potentially be groundbreaking advances in patient care and treatment efficacy.

Now more than ever, the need for innovative solutions in the landscape of neurological diseases is critical. As researchers gather at Keystone, Brenig’s promise of advancing healthcare through neuroinflammation-targeted therapeutics represents a beacon of hope for millions struggling with such conditions.